Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for TScan Therapeutics, Inc. (TCRX : NSDQ)

• Company Description    TScan Therapeutics Inc. is a biopharmaceutical company. It focused on the development of T-cell receptor engineered T cell therapies for the treatment of patients with cancer. The company's lead product pipeline consist TSC-100 and TSC-101. TScan Therapeutics Inc. is based in WALTHAM, Mass. Number of Employees: 142

• Price / Volume Information    Yesterday's Closing Price: $1.06 Daily Weekly Monthly 20 Day Moving Average: 585,687 shares Shares Outstanding: 56.90 (millions) Market Capitalization: $60.32 (millions) Beta: 1.03 52 Week High: $2.57 52 Week Low: $0.88 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 13.73% 16.06% 12 Week 17.66% 20.81% Year To Date 6.00% 8.31%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 830 WINTER STREET - WALTHAM,MA 02451 USA ph: 857-399-9500 fax: - hsavelle@tscan.com http://www.tscan.com

• General Corporate Information    Officers Gavin MacBeath - Chief Executive Officer and Director Jason A. Amello - Chief Financial Officer Katina Dorton - Director Gabriela Gruia - Director Barbara Klencke - Director Peer Information TScan Therapeutics, Inc. (CORR.) TScan Therapeutics, Inc. (RSPI) TScan Therapeutics, Inc. (CGXP) TScan Therapeutics, Inc. (BGEN) TScan Therapeutics, Inc. (GTBP) TScan Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 89854M101 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 12/01/25 Next Expected EPS Date: 05/05/26 Share - Related Items Shares Outstanding: 56.90 Most Recent Split Date: (:1) Beta: 1.03 Market Capitalization: $60.32 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.22 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.02 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 05/05/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.49 Price/Cash Flow: - Price / Sales: 5.84 EPS Growth vs. Year Ago Period: 37.93% vs. Previous Quarter: 35.71% Sales Growth vs. Year Ago Period: 286.02% vs. Previous Quarter: 2.23% ROE 12/31/25 - -79.36 09/30/25 - -73.33 06/30/25 - -63.33 ROA 12/31/25 - -46.25 09/30/25 - -44.76 06/30/25 - -40.19 Current Ratio 12/31/25 - 8.41 09/30/25 - 6.44 06/30/25 - 7.06 Quick Ratio 12/31/25 - 8.41 09/30/25 - 6.44 06/30/25 - 7.06 Operating Margin 12/31/25 - -1,256.81 09/30/25 - -1,680.02 06/30/25 - -1,949.22 Net Margin 12/31/25 - -1,256.81 09/30/25 - -1,692.96 06/30/25 - -1,964.88 Pre-Tax Margin 12/31/25 - -1,256.81 09/30/25 - -1,692.96 06/30/25 - -1,964.88 Book Value 12/31/25 - 2.16 09/30/25 - 2.54 06/30/25 - 3.11 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - 0.26 09/30/25 - 0.23 06/30/25 - 0.18 Debt-to-Capital 12/31/25 - 20.90 09/30/25 - 18.37 06/30/25 - 15.45

Powered by Zacks Investment Research ©